Using copper-depleting nanotechnology to treat triple-negative breast cancer
Copper-depleting nanotheranostics for treating triple negative breast cancer
This study is exploring a new way to help people with triple-negative breast cancer by using tiny particles to lower copper levels in tumors, which could slow down cancer growth and spread, offering hope for better treatment options.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Stanford University NIH-funded |
| Lab location | 1 site (Stanford, United States) |
| Project ID | NIH-10900851 on NIH RePORTER |
What this research studies
This research investigates a novel approach to treating triple-negative breast cancer (TNBC) by utilizing a nanotechnology platform designed to deplete excess copper in cancerous tissues. Copper is known to play a significant role in cancer progression, and this study aims to create a self-reporting system that effectively reduces copper levels, potentially inhibiting tumor growth and metastasis. By targeting the unique biochemical environment of TNBC, the research seeks to improve treatment outcomes for patients who currently have limited options. The methodology involves advanced nanotechnology to deliver copper-depleting agents directly to the tumor site, enhancing therapeutic efficacy.
Who could benefit from this research
Good fit: Ideal candidates for this research are women diagnosed with triple-negative breast cancer who have not responded well to existing therapies.
Not a fit: Patients with other subtypes of breast cancer or those who have not been diagnosed with breast cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new treatment option for patients with triple-negative breast cancer, potentially improving survival rates and quality of life.
How similar studies have performed: While the approach of using copper depletion in cancer treatment is recognized, this specific application of nanotechnology in TNBC is innovative and has not been extensively tested in prior studies.
Where this research is happening
Stanford, United States
- Stanford University — Stanford, United States (Active)
Researchers
- Principal investigator: Rao, Jianghong — Stanford University
- Study coordinator: Rao, Jianghong
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.